Bloom Burton lowered shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) from a buy rating to an accumulate rating in a research report sent to investors on Wednesday, March 14th.
Separately, HC Wainwright initiated coverage on shares of Aralez Pharmaceuticals in a report on Monday, February 5th. They issued a buy rating and a $6.00 target price on the stock.
Shares of ARLZ traded down $0.05 on Wednesday, hitting $1.40. 735,134 shares of the stock traded hands, compared to its average volume of 665,926. The company has a market capitalization of $97.17, a P/E ratio of -1.17 and a beta of 1.59. The company has a quick ratio of 0.68, a current ratio of 0.78 and a debt-to-equity ratio of 18.05. Aralez Pharmaceuticals has a one year low of $0.95 and a one year high of $2.98.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Tuesday, March 13th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). The firm had revenue of $28.02 million for the quarter, compared to the consensus estimate of $25.75 million. Aralez Pharmaceuticals had a negative net margin of 118.18% and a negative return on equity of 170.42%. sell-side analysts expect that Aralez Pharmaceuticals will post -0.66 EPS for the current year.
A hedge fund recently raised its stake in Aralez Pharmaceuticals stock. Goldman Sachs Group Inc. increased its stake in Aralez Pharmaceuticals (NASDAQ:ARLZ) by 159.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 261,606 shares of the company’s stock after purchasing an additional 160,621 shares during the quarter. Goldman Sachs Group Inc. owned 0.39% of Aralez Pharmaceuticals worth $371,000 at the end of the most recent quarter. 17.83% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/aralez-pharmaceuticals-arlz-stock-rating-lowered-by-bloom-burton.html.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.